Ortho Micronor (norethindrone)

No dosing information is available for this tab.

Norethindrone acetate is administered orally.

Norethindrone is administered orally once daily. The tablets should be taken at the same time each day and continued daily without interruption, including throughout all bleeding episodes. Women should be advised to inform a clinician if prolonged bleeding, amenorrhea, or severe abdominal pain occurs.

Levonorgestrel is administered orally or as a levonorgestrel-releasing intrauterine device.

If vomiting occurs within 2 hours following administration of levonorgestrel (e.g., Plan B One-Step(R), Next Choice One Dose(R)) for postcoital contraception, a clinician should be contacted to discuss the need for repeating the dose. If vomiting occurs within 2 hours following administration of the first or second dose of the levonorgestrel 2-dose regimen for emergency contraception, a clinician should be contacted to discuss the need for taking another dose.

Levonorgestrel-releasing intrauterine system should be inserted into the uterine cavity under strict aseptic conditions following a complete review of the patient's medical and social histories, exclusion of pregnancy, and physical examination (including pelvic examination, Papanicolaou test (Pap smear), and appropriate laboratory tests for other genital diseases (e.g., gonorrhea, chlamydia) as indicated). Special attention should be given to determining whether the woman is at risk for ectopic pregnancy or pelvic inflammatory disease (PID). Patients should be reexamined shortly after the first menstrual period following insertion of the device to verify that the device is properly positioned. The manufacturer's labeling should be consulted for proper methods of inserting and removing the levonorgestrel-releasing intrauterine system and for associated precautions.

Etonogestrel is administered as a nonbiodegradable implant that is inserted subcutaneously in the inner aspect of the upper arm. The manufacturer's labeling should be consulted for the proper method of administration and associated precautions.

No dosing information is available for this tab.

No dosing information is available for this tab.

For information on drug interactions associated with oral contraceptives, see Drug Interactions in Estrogen-Progestin Combinations 68:12.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

There is no enhanced messaging for this drug.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

No enhanced messaging available.

Although progestins have been used beginning in the first trimester of pregnancy to prevent habitual abortion or to treat threatened abortion, there is no adequate evidence from well-controlled studies to substantiate the efficacy of progestins for these uses; however, there is evidence of potential adverse effects on the fetus when these drugs are administered during the first 4 months of pregnancy. In addition, in most women, the cause of abortion is a defective ovum, which progestins could not be expected to influence. Because of their uterine-relaxant effects, progestins may delay spontaneous abortion of fertilized defective ova. Masculinization of the female fetus has reportedly occurred when progestins were used during pregnancy. Clitoral hypertrophy and fusion of the labia have been reported in a few female neonates born to women who had received medroxyprogesterone during pregnancy; hypospadias in male neonates born to women receiving progestational agents occurs at approximately twice the rate of occurrence in male neonates born to women not receiving the drugs. An association between intrauterine exposure to female sex hormones and congenital anomalies, including cardiovascular and limb defects, has been suggested. (See Cautions: Pregnancy, Fertility, and Lactation, in Estrogen-Progestin Combinations 68:12.) Use of progestins, including norethindrone, is not recommended during the first 4 months of pregnancy. If a woman becomes pregnant while receiving norethindrone or is inadvertently exposed to the drug during the first 4 months of pregnancy, she should be advised of the potential risks to the fetus.

Norethindrone should not be used to induce withdrawal bleeding as a test for pregnancy.

Progestins are reportedly distributed into milk. The manufacturers warn that the possible effects of progestins in milk on nursing infants have not been determined.

No enhanced messaging available.